跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 6,562 条关于
“enGene Holdings”
全部
6,562
临床试验
2,884
药物
1,399
机构
207
资讯
2,072
2年前
enGene Appoints Dr. Raj Pruthi as SVP to Advance EG-70 in Urologic Oncology
10个月前
enGene Holdings Reports 63% Complete Response Rate in Phase 2 Bladder Cancer Gene Therapy Trial
去年
enGene's Detalimogene Shows Promise in BCG-Unresponsive Bladder Cancer
8个月前
enGene Secures $125 Million Debt Facility to Advance Bladder Cancer Gene Therapy Toward FDA Approval
9个月前
enGene's Detalimogene Selected for FDA Manufacturing Pilot Program to Accelerate Bladder Cancer Gene Therapy Development
去年
FDA Grants RMAT Designation to Detalimogene for High-Risk Bladder Cancer
去年
Relmada Therapeutics Strengthens NDV-01 Bladder Cancer Program with Key Leadership Appointments Ahead of Phase 3 Trial
去年
Sareum's SDC-1801 Advances to Phase II Trials for Psoriasis Following Positive Phase I Results
去年
European Commission Approves Novo Holdings' $16.5B Catalent Acquisition
2年前
Bio-Path Holdings' BP1003 Demonstrates Therapeutic Potential in Diverse Cancers
第 1 页,共 208 页
上一页
下一页